Nonetheless, the current antagonistic treatments targeting IL-8 struggle to achieve favorable clinical outcomes, implying that alternative mechanisms could have a significant impact on CAFs-induced platinum resistance in pancreatic cancer cells. This evidence concerns the gene CXCL8 and pancreatic neoplasm.